RBC Capital analyst Ben Hendrix raised the firm’s price target on Elevance Health to $575 from $574 and keeps an Outperform rating on the shares after its Q1 earnings beat. The company has outperformed against a difficult managed care backdrop, with utilization across the benefit businesses tracking in line with expectations, the analyst tells investors in a research note. Evelnace’s Carelon brand also expands its reach through its CD&R primary care partnership, which brings the company carrier agnostic value-based care capabilities, RBC added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, April 18, 2024
- Elevance Health reports Medical membership totaled ~46.2M at March 31
- Elevance Health raises FY24 adjusted EPS view to greater than $37.20 per share
- Elevance Health reports Q1 adjusted EPS $10.64, consensus $10.53
- Notable companies reporting before tomorrow’s open